Korean J Gastroenterol.  2017 Dec;70(6):308-311. 10.4166/kjg.2017.70.6.308.

Effects of Long-term Maintenance Corticosteroid Therapy in Patients with Autoimmune Pancreatitis

• Park JM

• KMID: 2398883
• DOI: http://doi.org/10.4166/kjg.2017.70.6.308

Abstract

No abstract available.

MeSH Terms

Humans
Pancreatitis*

Reference

References

1. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995; 40:1561–1568.

2. Kanno A, Masamune A, Okazaki K, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas. 2015; 44:535–539.

3. Hart PA, Kamisawa T, Brugge WR, et al. abdominal outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013; 62:1771–1776.

4. Kamisawa T, Chari ST, Giday SA, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011; 40:809–814.

5. Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis. Gut. 2009; 58:1438–1439.

6. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008; 134:706–715.

7. Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014; 49:961–970.

8. Nishimori I, Otsuki M. Study about steroid therapy for autoimmune pancreatitis. Annual Reports of Research Committee of Intractable Pancreatic Diseases supported by Ministry of Health, Labour and Welfare of Japan (in Japanese). 2008. 137–144.

9. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009; 58:1504–1507.

10. Shimizu S, Naitoh I, Nakazawa T, et al. Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid. Scand J Gastroenterol. 2015; 50:1411–1418.

11. Kubota K, Watanabe S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011; 46:834–842.

12. Miyamoto Y, Kamisawa T, Tabata T, et al. Short and long-term outcomes of diabetes mellitus in patients with autoimmune pancreatitis after steroid therapy. Gut Liver. 2012; 6:501–504.

13. Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol. 2009; 104:2295–2306.

14. Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014; 109:1675–1683.